Sustained and rapid improvements in patient reported outcomes for moderate-to-severe psoriasis patients with moderate and high BSA treated with ixekizumab: Side-by-side results from UNCOVER-3 and IXORA-S

被引：0
|
作者：
Bagel, Jerry [1 ]
Gottlieb, Alice B. [2 ]
Burge, Russel [3 ,4 ]
See, Kyoungah [3 ]
Garrelts, Alyssa [3 ]
McKean-Matthews, Missy [5 ]
Papp, Kim [6 ]
机构：
[1] Psoriasis Treatment Ctr Cent NJ, East Windsor, NJ USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Syneos Hlth, Raleigh, NC USA
[6] Prob Med Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
26032
引用
收藏
页码：AB82 / AB82
页数：1
相关论文
共 50 条
  • [1] Ixekizumab treatment results in more rapid clinical improvements in patients with moderate-to-severe psoriasis compared with ustekinumab: Results from the IXORA-S trial
    Pinter, Andreas
    Amato, David
    Burge, Russel
    Dong, Yan
    Zhu, Baojin
    Shrom, David
    Gallo, Gaia
    Lomaga, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB230 - AB230
  • [2] An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
    Puig, Lluis
    Lomaga, Mark
    Hollister, Kristin
    Dutronc, Yves
    Berggren, Lovisa
    van de Kerkhof, Peter C. M.
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 7
  • [3] Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
    Reich, K.
    Pinter, A.
    Lacour, J. P.
    Ferrandiz, C.
    Micali, G.
    French, L. E.
    Lomaga, M.
    Dutronc, Y.
    Henneges, C.
    Wilhelm, S.
    Hartz, S.
    Paul, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) : 1014 - 1023
  • [4] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Reich, Kristian
    Leonardi, Craig
    Lebwohl, Mark
    Kerdel, Francisco
    Okubo, Yukari
    Romiti, Ricardo
    Goldblum, Orin
    Dennehy, Ellen B.
    Kerr, Lisa
    Sofen, Howard
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
  • [5] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Wasel, Norman
    Thaci, Diamant
    French, Lars E.
    Conrad, Curdin
    Dutronc, Yves
    Gallo, Gaia
    Berggren, Lovisa
    Lacour, Jean-Philippe
    DERMATOLOGY AND THERAPY, 2020, 10 (04) : 663 - 670
  • [6] Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A. B.
    Sebastian, M.
    Wu, J. J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 477 - 482
  • [7] Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: Results from UNCOVER-2
    van de Kerkhof, Peter
    Guenther, Lyn
    Gottlieb, Alice
    Sebastian, Michael
    Wu, Jashin J.
    Foley, Peter
    Morita, Akimichi
    Goldblum, Orin
    Kerr, Lisa
    Rich, Phoebe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [8] 52-Week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis
    Paul, C.
    van de Kerkhof, P.
    Dutronc, Y.
    Henneges, C.
    Dossenbach, M.
    Hollister, K.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E293 - E293
  • [9] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Norman Wasel
    Diamant Thaçi
    Lars E. French
    Curdin Conrad
    Yves Dutronc
    Gaia Gallo
    Lovisa Berggren
    Jean-Philippe Lacour
    Dermatology and Therapy, 2020, 10 : 663 - 670
  • [10] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    LANCET, 2015, 386 (9993): : 541 - 551
12345